信迪利单抗联合同步放化疗用于晚期宫颈癌患者的效果  

Effects of Sintilimab combined with concurrent chemoradiotherapy in treatment of patients with advanced cervical cancer

作　　者：张哲 何亚歌 石杨磊 ZHANG Zhe;HE Yage;SHI Yanglei(Department of Pharmacy of Pingdingshan People’s Hospital No.1,Pingdingshan 467000 Henan,China)

机构地区：[1]平顶山市第一人民医院药学部,河南平顶山467000

出　　处：《中国民康医学》2023年第20期64-67,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察信迪利单抗联合同步放化疗用于晚期宫颈癌患者的效果。方法:选取2021-2022年该院收治的64例晚期宫颈癌患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各32例。对照组予以同步放化疗,观察组在对照组基础上联合信迪利单抗治疗。比较两组临床疗效,治疗前后血清学指标[鳞状上皮细胞癌抗原(SCC)、血小板与淋巴细胞比值(PLR)、淋巴细胞与单核细胞比值(LMR)]水平、卡氏(KPS)评分,以及不良反应发生率。结果:观察组疾病控制率(DCR)为84.38%(27/32),高于对照组的59.38%(19/32),差异有统计学意义(P<0.05);治疗后,观察组PLR、SCC水平均低于对照组,LMR水平高于对照组,差异有统计学意义(P<0.05);治疗后,观察组KPS评分高于对照组,差异有统计学意义(P<0.05);两组皮疹、肝肾功能异常、胃肠道反应、放射性膀胱炎、骨髓抑制等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:信迪利单抗联合同步放化疗用于晚期宫颈癌患者可提高DCR和KPS评分,改善血清学指标水平,效果优于单纯同步放化疗。Objective:To observe effects of Sintilimab combined with concurrent chemoradiotherapy in treatment of patients with advanced cervical cancer.Methods:A prospective study was conducted on 64 patients with advanced cervical cancer admitted to this hospital from 2021 to 2022.They were divided into control group and observation group according to the random number table method,32 cases in each group.The control group was treated with concurrent chemoradiotherapy,while the observation group was treated with Sintilimab on the basis of that of the control group.The clinical efficacy,the serological indexes[squamous cell carcinoma antigen(SCC),platelet-to-lymphocyte ratio(PLR),lymphocyte-to-monocyte ratio(LMR)]levels,the KPS score and incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The disease control rate(DCR)of the observation group was 84.38%(27/32),which was higher than 59.38%(19/32)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PLR and SCC in the observation group were lower than those in the control group,the level of LMR was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the KPS score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as rash,abnormal liver and kidney function,gastrointestinal reaction,radioactive cystitis and bone marrow suppression between the two groups(P>0.05).Conclusions:Sintilimab combined with concurrent chemoradiotherapy in the treatment of the patients with advanced cervical cancer can improve the DCR and KPS scores and improve the levels of serological indexes.Moreover,it is superior to single concurrent chemoradiotherapy.

关 键 词：晚期 宫颈癌 同步放化疗 信迪利单抗 疾病控制率 卡氏评分 不良反应 

分 类 号：R737[医药卫生—肿瘤]